Bello, ClaudiaCea, MicheleDal Bello, GiovannaGaruti, AnnaRocco, IlariaCirmena, GabriellaMoran, EvaNahimana, AimableDuchosal, Michel A.Fruscione, FlorianaPronzato, PaoloGrossi, FrancescoPatrone, FrancoBallestrero, AlbertoDupuis, MarcSordat, BernardNencioni, AlessioVogel, Pierre2011-12-162011-12-162011-12-16201010.1016/j.bmc.2010.03.009https://infoscience.epfl.ch/handle/20.500.14299/75564WOS:000277083400034Novel alpha-mannosidase inhibitors of the type (2R,3R,4S)-2-({[(1R)-2- hydroxy-1-arylethyl]amine}methyl) pyrrolidine-3,4-diol have been prepared and assayed for their anticancer activities. Compound 30 with the aryl group = 4-trifluoromethylbiphenyl inhibits the proliferation of primary cells and cell lines of different origins, irrespective of Bcl-2 expression levels, inducing a G2/Mcell cycle arrest and by modification of genes involved in cell cycle progression and survival. (C) 2010 Elsevier Ltd. All rights reserved.Glycosylationalpha-Mannosidase inhibitorsAntiproliferative effectsCell cycleHaematological malignancesN-Linked GlycansEndoplasmic-ReticulumHuman GlioblastomaCell SurvivalCancer-CellsGlycosylationSwainsonineLymphomaGrowthBcl-2Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignanciestext::journal::journal article::research article